(b) (4)

(b) (6)



Laura S. Levy, Ph.D. Professor of Microbiology and Immunology Vice President for Research May 7, 2018

Brent Morse, DVM Acting Director Division of Compliance Oversight Office of Laboratory Animal Welfare ("OLAW") Via email: morseb@mail.nih.gov

Initial and Final Report re. Noncompliance: Semi-annual Inspections Conducted in January and February of Calendar Year 2018

Dear Dr. Morse:

Tulane University, in accordance with Animal Welfare Assurance and PHS Policy IV.F.3, provides this initial and final report of noncompliance regarding the following reportable issues identified during the IACUC's semiannual inspections conducted during January and February of 2018 and where the research was funded by the PHS, NSF, or VA:

Protocol No.	Species	Reportable Issue	Corrective Actions	Completion Status	Funding
0184R5	Mice	Noncompliance with approved protocol.	PI and lab staff were contacted on January 25, 2018 to purchase appropriate analgesia. The IACUC required Post Approval Monitoring ("PAM") for the next scheduled procedure to observe and ensure protocol adherence.	The appropriate analgesia has been purchased. No procedures have been conducted as of the date of this letter in order for PAM to occur. Noncompliance, if any, will be responded to with appropriate measures.	NIH
4172R2	Mice	Expired xylazine was not separate from in-date drug supply. Lab records indicate that the expired xylazine was used.	Lab staff was instructed regarding labeling expired drugs and separating from the in-date supply. Lab was sent instructions on hazardous waste pickup in order to dispose of expired xylazine.	Initial email sent January 26, 2018 with follow-up confirmation on March 14, 2018 regarding completion of acquisition of in-date xylazine.	NIH

Page 2 of 2 May 7, 2018 Brent Morse, DVM

For each of the reportable events listed above, Tulane determined that the financial impact of the noncompliance is *de minimis* and not of a level necessitating financial reconciling and reporting to the respective sponsoring entities.

Tulane University is committed to protecting the welfare of animals used in research and appreciates the guidance and assistance provided by OLAW in this regard. Those individuals courtesy copied on this report worked most closely on the matter and can be contacted if you have any questions.

Thank you for your consideration of this matter.

Yours sincerely,

(b) (6)

Laura S. Levy, PhD Professor of Microbiology and Immunology Vice President for Research and Institutional Official Tulane University

cc: Sheila Garrison, Tulane IACUC Chair and Director (via email) Georgina Dobek, DVM, DACLAM, Tulane University Director of Comparative Medicine (via email)

## Morse, Brent (NIH/OD) [E]

From:Morse, Brent (NIH/OD) [E]Sent:Tuesday, May 08, 2018 7:14 AMTo:(b) (6)Cc:Levy, Laura S; Garrison, Sheila H; Dobek, Georgina LSubject:RE: Initial and Final Report - Noncompliance

Thank you for reporting these issues (b) (6) We will send an official response soon. In the future, please send reports to OLAWDCO@mail.nih.gov so that your messages can be monitored by other DCO staff in my absence. Thank you again.

Regards, Brent Morse

Brent C. Morse, DVM, DACLAM Acting Director Division of Compliance Oversight Office of Laboratory Animal Welfare National Institutes of Health

Please note that this message and any of its attachments are intended for the named recipient(s) only and may contain confidential, protected or privileged information that should not be distributed to unauthorized individuals. If you have received this message in error, please contact the sender.

From: (b) (6) @tulane.edu] Sent: Monday, May 07, 2018 6:17 PM To: Morse, Brent (NIH/OD) [E] <morseb@mail.nih.gov> Cc: Levy, Laura S <llevy@tulane.edu>; Garrison, Sheila H <sgarriso@tulane.edu>; Dobek, Georgina L <gdobek@tulane.edu> Subject: Initial and Final Report - Noncompliance

Dear Dr. Morse:

Attached, please find the Tulane University Institutional Official's initial and final report regarding issues identified as part of the Tulane IACUC's semi-annual inspections conducted in January and February of 2018.

Thank you for your assistance and consideration, and please do not hesitate to contact us if you have questions or require further information.

Sincerely,

(b) (6)

## web: http://www2.tulane.edu/asvpr/research-compliance.cfm

This email transmission, including attachments, if any, contains confidential and/or privileged information and is intended solely for the use of the sender's intended recipient(s). Any unauthorized review, use, disclosure or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender by return email and delete all references to this email transmission and its contents from your systems.